- You have no items in your shopping cart
- Subtotal: $0.00
Fatima
Posted on
RUFY1-RET fusion identified as mechanism of resistance to lorlatinib in lung cancer
Source: News-Medical.Net
A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report."
A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report."
In … [2329 chars]